Menu
Search
|

Menu

Close
X

Abeona Therapeutics Inc ABEO.OQ (NASDAQ Stock Exchange Capital Market)

16.55 USD
-- (--)
As of Jun 20
chart
Previous Close 16.55
Open --
Volume --
3m Avg Volume 249,539
Today’s High --
Today’s Low --
52 Week High 22.70
52 Week Low 4.75
Shares Outstanding (mil) 47.31
Market Capitalization (mil) 761.62
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.78 Mean rating from 9 analysts

KEY STATS

Revenue (mm, USD)
FY18
3
FY17
1
FY16
1
FY15
1
EPS (USD)
FY18
-0.180
FY17
-0.653
FY16
-0.637
FY15
-0.523
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.88
Price to Sales (TTM)
vs sector
234.42
8.30
Price to Book (MRQ)
vs sector
4.62
4.32
Price to Cash Flow (TTM)
vs sector
--
22.70
Total Debt to Equity (MRQ)
vs sector
0.00
17.35
LT Debt to Equity (MRQ)
vs sector
0.00
12.89
Return on Investment (TTM)
vs sector
-22.75
13.21
Return on Equity (TTM)
vs sector
-23.05
15.18

EXECUTIVE LEADERSHIP

Steven Rouhandeh
Executive Chairman of the Board, Since 2015
Salary: $370,000.00
Bonus: $220,000.00
Timothy Miller
President, Chief Scientific Officer, Since 2018
Salary: $359,000.00
Bonus: $148,000.00
Frank Thiel
Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Jeffrey Davis
Chief Operating Officer, Since 2017
Salary: $334,000.00
Bonus: $266,000.00
David Nowotnik
Senior Vice President - Research and Development, Since 2016
Salary: $129,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3333 Lee Pkwy Ste 600
DALLAS   TX   75219-5117

Phone: +1214.9055100

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

SPONSORED STORIES